Same-Day Co-Administration of Varicella and Inactivated Hepatitis A Vaccines in Children Aged 12 to 23 Months in Shandong, China
Timeliness, Parental Acceptability, and Safety of Same-Day Administration of Varicella and Hepatitis A Vaccines Among Children: An Observational Study
The goal of this observational study is to learn whether offering same-day co-administration of the varicella (chickenpox) vaccine and the inactivated hepatitis A vaccine at routine vaccination clinics helps children in China complete both vaccines on time, and how parents feel about this service.
The main questions it aims to answer are:
- Do parents accept same-day administration of the two vaccines when clinics offer this option?
- Are children more likely to complete both vaccines within 90 days when the same-day option is available?
Participants will receive routine vaccination care as usual. After clinic staff explain the options - both vaccines on the same day at different injection sites, on different days, or waiting - parents freely choose, and the study records the choice. Families who take part receive short follow-up contacts about 1 week, 1 month, and 6 weeks after each vaccination to ask about fever, rash, or other health problems, complete a short satisfaction survey at 1 month, and are followed for 90 days through immunization records. Results will also be compared with de-identified immunization records of similar children from the same clinics before the service was introduced.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Mingyue Geng
- Phone Number: +86-19812542317
- Email: gmy_cy@163.com
Study Locations
-
-
Shandong
-
Heze, Shandong, China, 274900
- Juye County Center for Disease Control and Prevention
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Children aged 12-23 months attending participating primary-level vaccination clinics in Shandong Province, China, who are due for the first dose of a live attenuated varicella vaccine and/or indicated doses of inactivated hepatitis A vaccine. Screening is consecutive on each vaccination day.
Description
Inclusion Criteria:
- Aged 12-23 months at screening.
- The immunization information system shows that the first dose of varicella vaccine and/or the indicated dose of inactivated hepatitis A vaccine is still due.
- Passes the clinician's health inquiry, contraindication screening and vaccination suitability assessment on the enrollment day.
- The guardian understands the study and signs written informed consent.
- The guardian is willing to accept study follow-up and can be contacted in person or by telephone for medical information verification.
Exclusion Criteria:
- Has already completed the doses of varicella vaccine and hepatitis A vaccine required for the study observations before screening.
- Previous severe allergic reaction to any component of the vaccines to be administered.
- Has a clear vaccination contraindication listed in the package inserts or national guidelines making inclusion in the study observations unsuitable.
- Recent use of immunoglobulin, blood products or immunosuppressive therapy affecting live vaccine scheduling, with no possibility of completing follow-up assessments within the observation windows.
- The guardian is unable to complete follow-up or refuses to provide necessary study information.
Children with temporary health conditions leading to deferral on that day may enter the Deferred/Unvaccinated Group for acceptance, service process and timeliness observations, but are not included in the post-vaccination safety analysis of that episode.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Same-Day Co-Administration Group
Children aged 12-23 months who, on the day of enrollment, are assessed by the vaccination clinician as eligible for both the first dose of a live attenuated varicella vaccine and an inactivated hepatitis A vaccine , and whose guardians voluntarily choose to receive both vaccines on the same calendar day at different injection sites. Children receive routine care including a 30-minute on-site observation period after vaccination, followed by active safety follow-up on Days 7 (+/-2), 30 (+/-5) and 42 (+/-7). Parental satisfaction is assessed at Day 30, and vaccination timeliness (completion of both vaccines, number of visits, reasons for delay) is tracked through Day 90 after screening. Co-administration of other age-appropriate vaccines (e.g., MMR, DTaP) is permitted and recorded; these children are analyzed as a prespecified subgroup. |
Live attenuated varicella vaccine (Oka strain), given as a single 0.5 mL subcutaneous dose according to the national immunization schedule and the vaccine label. In this non-interventional study the vaccine is administered as routine care; the study does not assign, modify, or delay any vaccination. This is the exposure of interest for the 0-42 day safety observation window, including delayed varicella-like rash. Inactivated hepatitis A vaccine, given intramuscularly in the upper arm according to the national immunization schedule and the vaccine label. In this non-interventional study the vaccine is administered as routine care; the study does not assign, modify, or delay any vaccination. This is the exposure of interest for the 0-30 day safety observation window. |
|
Separate-Day Administration Group
Children aged 12-23 months who are assessed as eligible for both vaccines on the same day, but whose guardians voluntarily choose to receive the varicella vaccine and the inactivated hepatitis A vaccine on different calendar days. Safety observation restarts for each administered vaccine, with an observation window of 30 days for the inactivated hepatitis A vaccine and 42 days for the live attenuated varicella vaccine, and active follow-up on Days 7, 30 and 42 after each vaccination. Completion of both vaccines, number of clinic visits, interval between doses, and reasons for delay are tracked through Day 90 after screening; parental satisfaction is assessed at Day 30. Children contribute to the overlapping exposure-based safety analysis sets according to the vaccine actually received at each visit, with the observation window restarting at each administration, so a child receiving both vaccines on separate days contributes to both sets. |
Live attenuated varicella vaccine (Oka strain), given as a single 0.5 mL subcutaneous dose according to the national immunization schedule and the vaccine label. In this non-interventional study the vaccine is administered as routine care; the study does not assign, modify, or delay any vaccination. This is the exposure of interest for the 0-42 day safety observation window, including delayed varicella-like rash. Inactivated hepatitis A vaccine, given intramuscularly in the upper arm according to the national immunization schedule and the vaccine label. In this non-interventional study the vaccine is administered as routine care; the study does not assign, modify, or delay any vaccination. This is the exposure of interest for the 0-30 day safety observation window. |
|
Deferred/Unvaccinated Group
Children aged 12-23 months who are assessed as eligible for vaccination on the day of screening, but whose guardians voluntarily choose to defer or not receive one or both of the study vaccines on that day (including temporary deferral for health reasons). This group does not contribute to post-vaccination safety analysis. It is followed only for acceptance-related and timeliness outcomes: completion of the two vaccines, number of clinic visits, and reasons for deferral or delay are tracked through Day 90 after screening. Guardians who decline study participation still receive routine vaccination services as usual. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acceptance rate of same-day co-administration
Time Frame: Day 0 (at enrollment, i.e., the day of the vaccination decision)
|
Proportion of children eligible for both vaccines on the same day whose guardians choose same-day co-administration of the varicella vaccine and the inactivated hepatitis A vaccine. Denominator: children in the core analysis set (assessed eligible for both vaccines on the enrollment day). Reported as a percentage with 95% confidence interval. |
Day 0 (at enrollment, i.e., the day of the vaccination decision)
|
|
Completion rate of both vaccines within 90 days
Time Frame: Through 90 days after screening
|
Proportion of children in the core analysis set who complete the study-relevant (due) doses of both the varicella vaccine and the inactivated hepatitis A vaccine within 90 days after screening. "Due doses" means the doses indicated at that visit and does not require completion of the full two-dose hepatitis A primary series within 90 days. Completion is verified through the immunization information system or guardians' vaccination records. Reported as a percentage with 95% confidence interval. This endpoint evaluates service delivery and short-term completion; the 90-day window is not a vaccine safety observation window. |
Through 90 days after screening
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Single-visit completion rate
Time Frame: Day 0
|
Proportion of children who complete all indicated study vaccines on the day of the first eligible visit. Denominator: children eligible for vaccination on that day. Reported as a percentage with 95% confidence interval. |
Day 0
|
|
Parental satisfaction score
Time Frame: Day 30 (+/-5) after screening/enrollment visit (S0); for children vaccinated at later visits, the schedule and unified anchor are specified in the study operations manual
|
Guardian-reported satisfaction assessed with service-evaluation items covering clarity of pre-vaccination information, adequacy of explanation of the co-administration options, convenience of scheduling and on-site procedures, waiting time, staff communication and overall satisfaction, using 5-point Likert scales; the proportion willing to recommend the service to other parents is also reported. Analysis population: guardians of children in the core analysis set. |
Day 30 (+/-5) after screening/enrollment visit (S0); for children vaccinated at later visits, the schedule and unified anchor are specified in the study operations manual
|
|
Delayed or incomplete vaccination and number of clinic visits
Time Frame: Through 90 days after screening
|
Proportion of children with delayed or incomplete vaccination beyond the recommended age window or within 90 days after screening, and the mean/median number of clinic visits required to complete both vaccines, compared between the post-implementation cohort and the historical control (pre-implementation) cohort using chi-square tests, rank-sum tests and multivariable adjustment or propensity score methods where appropriate. |
Through 90 days after screening
|
|
Incidence of solicited adverse events within 7 days after vaccination
Time Frame: 0-7 days after vaccination
|
Incidence of solicited local reactions (pain/tenderness, erythema, swelling, induration, rash, itching) and systemic reactions (fever, acute allergic manifestations, diarrhea, nausea, vomiting, decreased appetite, abnormal crying, decreased activity) within 0-7 days after vaccination, collected by active follow-up on Day 7 (+/-2). Analyzed descriptively by vaccine exposure (same-day vs separate-day administration) with 95% confidence intervals. |
0-7 days after vaccination
|
|
Incidence of adverse events within 30 days after hepatitis A vaccination
Time Frame: 0-30 days after hepatitis A vaccination
|
Incidence of adverse events (AE) and serious adverse events (SAE) within 0-30 days after administration of the inactivated hepatitis A vaccine, including suspected adverse events following immunization (AEFI). Collected by 30-minute on-site observation, active follow-up on Days 7, 30 (+/-5) and 42 (+/-7), medical records review, and linkage to the national AEFI surveillance system. Analysis population: all doses of inactivated hepatitis A vaccine actually administered to study children, regardless of enrollment group (hepatitis A exposure analysis set); the observation window restarts at each administration, each dose contributes one 30-day observation, and the hepatitis A and varicella exposure sets overlap and are therefore not additive. Reported as percentages with 95% confidence intervals. |
0-30 days after hepatitis A vaccination
|
|
Incidence of adverse events within 42 days after varicella vaccination
Time Frame: 0-42 days after varicella vaccination
|
Incidence of AE and SAE within 0-42 days after administration of the live attenuated varicella vaccine, with particular attention to delayed varicella-like rashes and fever, including AEFI. Collected by 30-minute on-site observation, active follow-up on Days 7, 30 (+/-5) and 42 (+/-7), medical records review, and linkage to the national AEFI surveillance system. Analysis population: all doses of live attenuated varicella vaccine actually administered to study children, regardless of enrollment group (varicella exposure analysis set); the observation window restarts at each administration, each dose contributes one 42-day observation, and the varicella and hepatitis A exposure sets overlap and are therefore not additive. Reported as percentages with 95% confidence intervals. |
0-42 days after varicella vaccination
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Liping Yang, Shandong University
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1320026019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
De-identified individual participant data that underlie the results reported in this article will be made available, beginning 3 months and ending 5 years following article publication. Data will be shared with investigators whose proposed use of the data has been approved by an independent review committee. Proposals should be directed to the corresponding author.
IPD Sharing Time Frame
Beginning 3 months and ending 5 years following the publication of the main study results.
IPD Sharing Access Criteria
Researchers who provide a methodologically sound proposal and have obtained approval from an independent review committee. Data will be shared upon execution of a data use agreement. Proposals should be directed to the corresponding author.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.